---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-24-000014"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:22:45.599106+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Entrada Therapeutics FY2023 net loss $6.7M, cash $352M; DMD Phase 1 data on track

## Summary
- Cash, equivalents and marketable securities $352.0M as of Dec 31, 2023, up from $188.7M; runway through Q2 2026.
- Collaboration revenue $129.0M full year (Vertex deal); net loss narrowed to $6.7M from $94.6M in 2022.
- Completed dosing first three cohorts of ENTR-601-44 Phase 1 for DMD; data readout H2 2024.
- Regulatory applications expected Q4 2024 for global Phase 2 of ENTR-601-44 and ENTR-601-45.
- Promoted Nathan Dowden to President & COO; appointed Kevin Healy (SVP Regulatory) and Marie Rosenfeld (SVP Clinical Ops).

## SEC filing metadata
- accession: 0001689375-24-000014
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937524000014/0001689375-24-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937524000014/trda-20240313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-24-000014
- JSON: https://secwatch.observer/filing/0001689375-24-000014.json
- Plain text: https://secwatch.observer/filing/0001689375-24-000014.txt

## Key facts
- Earnings Releases
  Entrada Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss was $6.7 million for the full year of 2023.
  - Period: the year ended December 31, 2023
  - Net income: Net loss was $6.7 million for the full year of 2023
  - Result: reported results
  source text: On March 13, 2024, Entrada Therapeutics, Inc. announced its financial results for the year ended December 31, 2023 and other corporate updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000168937524000014/0001689375-24-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.